Brokers Issue Forecasts for Moderna FY2029 Earnings

Key Points

• Brookline Capital Markets slightly cut its FY2029 EPS forecast for Moderna to $11.83 (from $11.89) and projects FY2030 EPS of $19.45, signaling modest near‑term adjustment but bullish longer‑term expectations.
• Moderna's Q1 results showed a revenue beat of $389M (up ~260% YoY) driven by international COVID‑19 vaccine sales, but GAAP EPS missed at $(3.40) largely because of a one‑time $0.9B litigation settlement that widened the loss.
• Analyst sentiment is mixed—2 Buys, 12 Holds and 5 Sells—with an average rating of "Reduce" and a consensus price target of $34.60; individual targets range from RBC's $30 to Goldman's $49.

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Equities research analysts at Brookline Capital Markets dropped their FY2029 EPS estimates for shares of Moderna in a report issued on Friday, May 1st. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $11.83 per share for the year, down from their prior forecast of $11.89. The consensus estimate for Moderna's current full-year earnings is ($8.00) per share. Brookline Capital Markets also issued estimates for Moderna's FY2030 earnings at $19.45 EPS.

Several other brokerages have also issued reports on MRNA. Royal Bank Of Canada lifted their price target on Moderna from $25.00 to $30.00 and gave the stock a "sector perform" rating in a research note on Tuesday, February 17th. Leerink Partners reiterated an "underperform" rating on shares of Moderna in a research report on Friday, January 30th. TD Cowen reissued a "hold" rating on shares of Moderna in a report on Thursday, January 29th. The Goldman Sachs Group restated a "neutral" rating and issued a $49.00 target price on shares of Moderna in a research report on Friday. Finally, Wall Street Zen raised Moderna from a "sell" rating to a "hold" rating in a research note on Saturday, January 17th. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Reduce" and a consensus target price of $34.60.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $45.37 on Monday. The firm has a market capitalization of $17.92 billion, a PE ratio of -5.57 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. Moderna has a 52-week low of $22.28 and a 52-week high of $59.55. The firm has a fifty day moving average of $51.84 and a 200 day moving average of $39.47.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company had revenue of $389.00 million for the quarter, compared to analysts' expectations of $236.37 million. During the same quarter last year, the business posted ($2.52) EPS. The business's quarterly revenue was up 260.2% compared to the same quarter last year.

Insider Activity

In other news, President Stephen Hoge sold 160,009 shares of the firm's stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president directly owned 1,457,427 shares of the company's stock, valued at approximately $71,180,734.68. This trade represents a 9.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.80% of the company's stock.

Institutional Investors Weigh In On Moderna

Institutional investors have recently bought and sold shares of the stock. MUFG Securities EMEA plc bought a new stake in Moderna in the second quarter valued at approximately $28,000. Flagship Harbor Advisors LLC bought a new position in shares of Moderna in the fourth quarter worth approximately $31,000. Canton Hathaway LLC bought a new position in shares of Moderna in the first quarter worth approximately $31,000. Ameriflex Group Inc. increased its stake in shares of Moderna by 3,775.0% in the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company's stock worth $32,000 after buying an additional 1,208 shares during the period. Finally, Cromwell Holdings LLC increased its stake in shares of Moderna by 39.7% in the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company's stock worth $35,000 after buying an additional 341 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Q1 revenue sharply exceeded estimates — $389M (+~260% YoY) driven by strong international COVID‑19 vaccine sales, showing demand outside the U.S. and a meaningful top‑line rebound. Article Title
• Positive Sentiment: Pipeline and upcoming regulatory catalysts remain market drivers — the mRNA‑1010 seasonal flu PDUFA (Aug. 5) and advancing oncology programs give upside optionality beyond COVID vaccines. Article Title
• Neutral Sentiment: Company reiterated 2026 outlook (up to ~10% revenue growth) and signaled continued operating expense reductions excluding the non‑recurring settlement — suggests management expects sustainable margin improvements over time. Article Title
• Neutral Sentiment: Revenue concentration shifted heavily to ex‑U.S. markets (~80% of Q1 revenue), which helped the beat but increases sensitivity to international procurement cycles and government deals. Article Title
• Negative Sentiment: A $0.9B one‑time litigation settlement was recorded in Q1, producing a wider GAAP loss (GAAP EPS of $(3.40)) and negative gross/net margins — this sizable charge weighed on the earnings print despite the revenue beat. Article Title
• Negative Sentiment: Stock reaction was volatile — shares initially rallied on the revenue beat but later moved lower as investors digested the settlement, continued unprofitability, and reliance on a few government contracts. Article Title

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.